Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab
Author:
Affiliation:
1. Division of Neurology, Kobe University Graduate School of Medicine
Publisher
Societas Neurologica Japonica
Subject
Neurology (clinical)
Link
https://www.jstage.jst.go.jp/article/clinicalneurol/59/8/59_cn-001307/_pdf
Reference24 articles.
1. 1) Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-66.
2. 2) Saida T, Kira JI, Kishida S, et al. Safety and efficacy of natalizumab in Japanese patients with relapsing-remitting multiple sclerosis: Open-label extension study of a phase 2 trial. Neurol Ther 2017;6:39-55.
3. 3) Oliver B, Fernandez O, Orpez T, et al. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler 2011;17:368-371.
4. 4) Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011;17:708-719.
5. 5) Outteryck O, Ongagna JC, Zephir H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 2010;257:207-211.
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of effector T cells in multiple sclerosis;Clinical and Experimental Neuroimmunology;2020-05-13
2. Fingolimod/natalizumab;Reactions Weekly;2019-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3